Advertisement

Topics

H3 Biomedicine Reports Discovery of Recurrent RNA Splicing Factor Mutations in Non-Hodgkin’s Lymphoma and Multiple Myeloma

09:00 EDT 17 Apr 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
-- Expands potential addressable patient population for H3 Biomedicine’s lead splicing modulator H3B-8800, currently in Phase 1 study for other hematologic malignancies -- -- Underscores promise of H3 Biomedicine’s ...

Other Sources for this Article

H3 Biomedicine Inc.
Media Inquiries
Liz Melone, 617-256-6622
elizabeth_melone@h3biomedicine.com
or
Investor Inquiries
Christina Tartaglia, 212-362-1200
christina@sternir.com

NEXT ARTICLE

More From BioPortfolio on "H3 Biomedicine Reports Discovery of Recurrent RNA Splicing Factor Mutations in Non-Hodgkin’s Lymphoma and Multiple Myeloma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...